23andMe Sold to TTAM Research Institute, a Nonprofit Public Benefit Corporation

23andMe, Inc.

Mon, Jun 30, 2025, 5:00 AM 6 min read

SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a genetics-led consumer healthcare company, today announced that it has received approval from the U.S. Bankruptcy Court for the Eastern District of Missouri (the “Court") for the sale of substantially all of the Company's assets and ongoing business operations to TTAM Research Institute (“TTAM”), a nonprofit public benefit corporation based in California and led by 23andMe Co-Founder and former CEO Anne Wojcicki. The transaction is expected to close in the coming weeks, subject to customary closing conditions.

"This approval marks a significant milestone in our Court proceedings and solidifies the path forward to ensure that 23andMe’s founding mission of helping people access, understand and gain health benefits through greater understanding of the human genome lives on globally,” said Mark Jensen, Chair of the Board and member of the Special Committee of the Board of Directors of 23andMe. “We remain focused on completing the steps necessary to finalize the transaction in the weeks ahead so the Company can move into its next chapter as a nonprofit.”

Under the terms of the agreement, TTAM will acquire substantially all of the assets of 23andMe, including the Personal Genome Service (PGS) and Research Services business lines and the Lemonaid Health business, for a purchase price of $305 million.

“I am thrilled that TTAM will be able to build on the mission of 23andMe to help people access, understand and benefit from the human genome. As a nonprofit, TTAM will be a champion of improving our knowledge of DNA – the code of life – for the public good, creating a resource to advance human health globally,” said Ms. Wojcicki. “Core to my beliefs is that individuals should be empowered to have choice and transparency with respect to their genetic data and have the opportunity to continue to learn about their ancestry and health risks as they wish. The future of healthcare belongs to all of us.”

TTAM is committed to providing customers with choice and transparency with their data, including the option to change their decision on whether to participate in research. To that end, all customers will be emailed in advance of the transaction closing with a notice of the sale. TTAM is committed to adhering to 23andMe’s existing privacy policies in perpetuity, and is adopting additional consumer protections and privacy safeguards to enhance protections for customer data and privacy.

Additional information regarding 23andMe’s Chapter 11 filing, proceedings and claims process is available at https://restructuring.ra.kroll.com/23andMe. Questions about the claims process should be directed to the Company’s claims agent, Kroll, at [email protected] or by calling (888) 367-7556.